reason report
sight unclear genesight near-term
bottom line report slightli
street us unexpect item impact
genesight quarter genesight experienc revenu
adjust quarter actual cash collect fell behind
payment recal earlier impact medicar
document requir claim submit
genesight remain key driver long-term outlook
back-to-back challeng growth believ investor like
wait longer look sign potenti upsid busi
reimburs recal counsyl prenat busi also lost
in-network statu unh/op last quarter rais
level uncertainti remain market perform pt
genesight face anoth qtr hurdl gain reimburs
time payment guid studi publish
review payer investor focu improv
reimburs anoth set hurdl appear
genesight experienc revenu adjust due
collect fall behind larg due lbm scrutin payment
given window review cash collect
led take adj render genesight
outlook even murkier previous anticip recal
fda approv consum pharmacogenom test could
potenti compet genesight also continu keep overhang
genesight
anoth reimburs uncertainti brew
transmitt elimin coverag brca hereditari gene
test certain criteria met controversi
on-going sinc novemb post transmitt
contractor cover brca gene test certain condit larg
advanc cancer met led confus among
compani industri wide though believ polici
go effect commun call
impact commerci coverag brca test given industry-
wide pushback believ situat like get resolv soon
guid estim chang reiter guid
revenue ep vs con
issu new guid revenue ep
vs con lower rev slightli
slightli rais ep
estim rev vs prior ep
vs base slower growth increas profit
net debt total capit
life scienc tool diagnost
blend dcf price-to-earnings
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm oper ep present includ effect stock option expens reflect adjust per recent file
pleas refer page import disclosur price chart analyst certif
continu stori transform hereditari cancer test leader
revenu compani that diversifi test portfolio recent
year acquir bolt-on compani offer test special area relat
hereditari test despit view hereditari test remain declin busi
price pressur strengthen test base recent acquisit counsyl
reproduct test prior acquisit assurex health
pharmacogenom test given loss patent protect posit brca
test hc test busi expect see heat competit
smaller entrant op genedx ambri genet larger refer lab
lh competit price unfold competitor becom even agil
pama protect access medicar act medicar price pressur expect
price remain pressur longer term hc test done good job
reimburs year success mitig price risk
nevertheless believ competitor lower continu drive penetr
market take market share lower cost genet test becom widespread
loss patent brca gene test longer protect posit
ovarian breast cancer test expect test revenu continu declin
gradual despit slight volum growth still market share brca test
market base revenu entrant provid genet test lower cost
believ mygn market share begin erod privat payer renegoti lower
contract rate expect genet test industri grow rate y/i certain
diseas test etc grow greater
light headwind undergo transform phase compani
diversifi test portfolio recent year acquir bolt-on compani offer
test special area relat hc howev see challeng new
product portfolio gain traction coverag without adequ commerci coverag
attempt obtain broader commerci reimburs genesight product
remain largest contributor upsid view reimburs per test
remain uncertain econom payer studi publish remain market perform
await public data improv reimburs
trade price-to-earnings believ blend dcf analysi price-to-earnings
appropri given growth potenti test legaci hereditari cancer
busi use blend averag price-to-earnings among peer dcf
analysi valu reach price target dcf includ long-term growth
equiti risk premium beta
could get broader adopt among commerci payer result aggress
negoti contract could lead signific upsid revenu gener
success negoti hc test contract given well-entrench posit
commun oncologist could potenti replic market well
inclus test nccn uspstf other could benefit test futur
drive signific payer adopt improv coverag test repres upsid risk
estim recommend medic societi includ american colleg
neuropsychiatri potenti drive chang guidelin could lead improv
coverag revenu upsid genesight
qualiti control problem among test competitor could drive volum
problem recent highlight despit impact limit believ
qualiti control issu competitor could drive provid use
establish hc test clinvar databas qualiti improv time would
embolden variant databas even believ
fda could regul ldt lab develop test increas pressur smaller lab
resourc believ like fare better vs competit chang
consolid within industri also mean could target given patient
databas wealth proprietari inform collect year could
view databas person medicin inform patient recruit
companion diagnost could growth driver sector longer term still lever
believ could present upsid portfolio test evolv biomark requir
therapi select therapi manag
dollar thousand except per share data
good sold
net incom non-control interest
sg sale
 sale
oper expens sale
compani file svb leerink research estim
